SMT Discover - Rial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in http://discover.societymusictheory.org/story.php?title=rial-of-the-mek12-inhibitor-selumetinib-as-monotherapy-versus-temozolomide-in-118 Rial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012, 18:555-567. Infante JR, Fecher LA, Nallapareddy S, Gordon MS, Flaherty KT, Cox DS, DeMarini DJ, Morris SR, Burris HA, Messersmith WA: Safety and efficacy results from the first-in-human s Wed, 14 Nov 2018 03:52:52 UTC en